Journal of Clinical Epidemiology
Volume 51, Issue 2 , Pages 69-79 , February 1998

A Study in Contrasts: Eligibility Criteria in a Twenty-Year Sample of NSABP and POG Clinical Trials

  • Abraham Fuks

      Affiliations

    • Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    • Clinical Trials Research Group, McGill University, Montreal, Quebec, Canada
    • ,
  • Charles Weijer

      Affiliations

    • Mount Sinai Hospital, Toronto, Ontario, Canada
    • University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationCharles Weijer, M.D., Ph.D., Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5
    • ,
  • Benjamin Freedman

      Affiliations

    • Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada
    • Clinical Trials Research Group, McGill University, Montreal, Quebec, Canada
    • ,
  • Stanley Shapiro

      Affiliations

    • Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    • Clinical Trials Research Group, McGill University, Montreal, Quebec, Canada
    • ,
  • Myriam Skrutkowska

      Affiliations

    • Clinical Trials Research Group, McGill University, Montreal, Quebec, Canada
    • ,
  • Amina Riaz

      Affiliations

    • Clinical Trials Research Group, McGill University, Montreal, Quebec, Canada

,Accepted 7 October 1997.

References 

  1. Friedman MA, Cain DF. National Cancer Institute sponsored cooperative clinical trials. Cancer. 1990;65:2376–2382
  2. American Medical Association Council on Scientific Affairs . Viability of cancer clinical research (Patient accrual, coverage, and reimbursement). J National Cancer Institute. 1991;83:254–259
  3. Wittes RE, Friedman MA. Accrual to clinical trials. (Editorial). J National Cancer Institute. 1988;80:884–885
  4. Frelick RW. The Community Clinical Oncology Program (CCOP) story (Review of community oncologists' experiences with clinical research trials in cancer with an emphasis on the CCOP of the National Cancer Institute between 1982 and 1987). J Clin Oncol. 1994;12:1718–1723
  5. Cobau CD. Clinical trials in the community (The Community Clinical Oncology Program experience). Cancer. 1994;74(Suppl.):2694–2700
  6. Cottman CA. The SWOG experience with CCOP's. J Cancer Program Manage. 1986;1:19–22
  7. Begg CB, Carbone PP, Elson PJ, Zelen M. Participation of community hospitals in clinical trials (Analysis of five years of experience in the Eastern Cooperative Oncology Group). N Engl J Med. 1982;306:1076–1080
  8. Gotay CC. Accrual to cancer research trials (Directions from the research literature). Social Sci Med. 1991;33:569–577
  9. Taylor KM, Margolese RG, Soskolne CL. Physician's reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med. 1984;310:1363–1367
  10. Mansour EG. Barriers to clinical trials. Part III (Knowledge and attitudes of health care providers). Cancer. 1994;74(Suppl.):2672–2675
  11. Benson AB, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials (An Illinois Cancer Center study). J Clin Oncol. 1991;9:2067–2075
  12. Taylor KM, Feldstein ML, Skeel RT, Pandya KJ, Ng P, Carbone PP. Fundamental dilemmas of the randomized clinical trial process (Results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators). J Clin Oncol. 1994;12:1796–1805
  13. Langley GR, Sutherland HJ, Wong S, Minkin S, Llewellyn-Thomas HA, Till JE. Why are (or are not) patients given the option to enter clinical trials?. Control Clin Trials. 1987;8:49–59
  14. Morrow GR, Hickok JT, Burish TG. Behavioral aspects of clinical trials (An integrated framework from behavior theory). Cancer. 1994;74(Suppl.):2676–2682
  15. Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S, Erlichman C. Patients' willingness to enter clinical trials (Measuring the association between perceived benefit and preference for decision participation). Social Sci Med. 1991;32:35–42
  16. Schain WS. Barriers to clinical trials. Part II (Knowledge and attitudes of potential participants). Cancer. 1994;74(Suppl.):2666–2671
  17. Llewellyn-Thomas HA, McGreal MJ, Theil EC. Cancer patients' decision making and trial-entry preferences. Med Decision Making. 1995;15:4–12
  18. Cassileth BR, Lusk EJ, Miller DS, et al.  Attitudes towards clinical trials among patients and the public. JAMA. 1982;248:968–970
  19. McCusker J, Wax A, Bennett JM. Cancer patient accessions into clinical trials (A pilot investigation into some patient and physician determinants of entry). Am J Clin Oncol. 1982;5:227–236
  20. Kotwall CA, Mahoney LJ, Myers RE, Decoste L. Reasons for nonentry in randomized clinical trials for breast cancer (A single institution study). J Surg Oncol. 1992;50:125–129
  21. Begg CB, Zelen M, Carbone PP, et al.  Cooperative groups and community hospitals (Measurement of impact in the community hospitals). Cancer. 1983;52:1760–1767
  22. Lee JY, Breaux SR. Accrual of radiotherapy patients to clinical trials. Cancer. 1983;52:1014–1016
  23. Weijer C. The breast cancer research scandal (Addressing the issues). Can Med Assoc J. 1995;152:1195–1197
  24. Boros L, Chuange C, Butler FO, Bennett JM. Leukemia in Rochester (A 17-year-experience with an analysis of the role of cooperative group (ECOG) participation). Cancer. 1985;56:2161–2169
  25. Karjalainen S, Palva I. Do treatment protocols improve end results? A study of the survival of patients with multiple myeloma in Finland. Br Med J. 1989;299:1069–1072
  26. Hjorth M, Holmberg E, Rodjer S, Westin J. Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. Br J Haematol. 1992;80:55–61
  27. Weijer C, Freedman B, Fuks A, Robbins J, Shapiro S, Skrutkowska M. What difference does it make to be treated on a clinical trial? A pilot study. Clin Invest Med. 1996;19:179–183
  28. Yusuf S, Collins R, Peto R. Why do we need large, simple trials?. Stat Med. 1984;3:409–420
  29. Sackett DL. On some prerequisites for a successful clinical trial. In:  Shapiro S,  Louis TA editor. Clinical Trials (Issues and Approaches). New York: Marcel Dekker, Inc; 1983;p. 65–79
  30. Yusuf S, Held P, Teo KK. Selection of patients for randomized controlled trials (Implications of wide or narrow eligibility criteria). Stat Med. 1990;9:73–86
  31. Buyse ME. The case for loose exclusion criteria in clinical trials. Acta Chir Belg. 1990;90:129–131
  32. George SL. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol. 1996;14:1364–1370
  33. Begg CB, Engstrom PF. Eligibility and extrapolation in cancer clinical trials. J Clin Oncol. 1987;5:962–968
  34. Fleiss JL. Statistical Methods for Rates and Proportions. 2. New York: John Wiley & Sons; 1981;212–236
  35. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. OPRR Reports. April 18, 1979: 1–8.
  36. Freedman B, Shapiro S. Ethics and statistics in clinical research (Towards a more comprehensive examination). J Stat Plan Inference. 1994;42:223–240
  37. Weijer C. Evolving ethical issues in the selection of subjects for clinical research. Cambridge Q Healthcare Ethics. 1996;5:334–345
  38. Department of Health and Human Services, National Institutes of Health . NIH Guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register. 1994;59:14508–14513
  39. Freedman B. Multicenter trials and subject eligibility (Should local IRBs play a role?). IRB (Review Human Subjects Res). 1994;16(1,2):1–6
  40. Kennedy BJ. Needed (Clinical trials for older patients). J Clin Oncol. 1991;9:718–720
  41. Mor V, Masterson-Allen S, Goldberg RJ, Cummings FJ, Glicksman AS, Fretwell MD. Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriat Soc. 1985;33:585–589
  42. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS. Choice of cancer therapy varies with age of patient. JAMA. 1986;255:3385–3390
  43. Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AN. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials (An Illinois Cancer Center study). J Clin Oncol. 1994;12:2447–2452
  44. Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly (The Piedmont Oncology Association experience). JAMA. 1992;268:57–62
  45. Weijer C, Fuks A. The duty to exclude (Excluding people at undue risk from research). Clin Invest Med. 1994;17:115–122
  46. Schwarz D, Lellouch J. Explanatory and pragmatic attitudes in therapetic trials. J Chron Dis. 1967;20:637–648
  47. Tate HC, Rawlinson JR. Randomized comparative studies in the treatment of cancer in the United Kingdom (Room for improvement?). Lancet. 1979;ii:623–625
  48. Meadows AT, Kramer S, Hopson R, Lustbader E, Jarret P, Evans AE. Survival in childhood acute lymphocytic leukemia (Effect of protocol and place of treatment). Cancer Invest. 1983;1:49–55

PII: S0895-4356(97)00240-0

Journal of Clinical Epidemiology
Volume 51, Issue 2 , Pages 69-79 , February 1998

Article Tools

* Image Usage & Resolution